Partners
Partners

Partner 26 - Alacris Theranostics


Alacris Theranostics

Dr. Bodo Lange

 

Principal Investigator

 

Phone: +49 30 8431 - 22510

 

undefinedE-Mail

 

Alacris Theranostics GmbH

 

Fabeckstrasse 60-62

14195 Berlin

Germany

 

undefinedWebsite

Company presentation

Alacris Theranostics GmbH (www.alacris.de) is a SME focusing on developing new approaches for personalised medicine, including Next Generation Sequencing (NGS) based treatment guidance, clinical trial stratification, biomarker discovery and advanced bioinformatics. Alacris holds an exclusive worldwide commercial license for the systems biology modelling system ModCellTM, a technology developed with the Max Planck Institute for Molecular Genetics, Berlin. The company is currently involved in a number of major research projects, contributing a range of technologies and expertise, including database creation and management, NGS, and development of the ModCellTM software for virtual patient modelling.

Current projects include: OncoTrack (IMI); TREGeneration (H2020); Epitreat (BMBF); SYBIL (FP7); Treat20plus (BMBF).

Within Cancer-ID, Alacris will participate as WP3 leader. Major tasks include establishment of a data integration platform, which will act as a central repository for the deposition of all primary data and standard operating procedures (SOPs) generated within the project. Alacris will also be involved in establishing SOPs and implementing analysis pipelines for identification of disease biomarkers.

CANCER-ID Consortium

CANCER-ID consortium

CANCER-ID Workpackages

CANCER-ID Work Plan

EUROPA - NEWS

News from the European Comission

What's new in Health and Life Sciences? Click here for news from the European Commission.

Search
Top
Home
Menu

EU logo
imi Logo
efpia Logo

News Section

Hands-on courses provided by our member TATAA Read more

Social Media

LinkedIn Cancer-ID